Global Epilepsy Therapeutics Market is Estimated to Value Over USD 15.2 Billion by 2026 End

  • 16 Oct 2019

Global Epilepsy Therapeutics Market is estimated to value over USD 15.2 billion by 2026 end and register a CAGR of over 3.2% during the forecast period 2019 to 2026.

The global epilepsy therapeutics market size is inflating at a high growth rate due to an ever-growing ageing population, increase in research and development activities in developing as well as developed markets and adoption of anti-epileptics owing to an increased number of epilepsy and seizure cases.

As per the WHO, epilepsy affects more than 40 million people across the world. In epilepsy, the brain starts to act abnormally, thus leading to frequent seizures that are short spans of involuntary movements, which may involve the entire body or a body part. These seizures sometimes result in causing unconsciousness and loss of bowel control or bladder function. Treatment with surgery or medication can curb these seizures in patients suffering from epilepsy.

Anti-epileptics are provided to treat epilepsy by curbing down seizures, and these medications work by decreasing the recurrent brain impulses that cause pain and seizures. High occurrence of epilepsy, increase in the prevalence of injuries to the brain and the increasing ageing population are crucial factors steering the epilepsy therapeutics market growth. Moreover, increased efficacy of future therapeutics related to epilepsy and growing acceptance and awareness of advanced medications amongst the patient population are predicted to stimulate the market in the upcoming years. 

The hospital pharmacies are predicted to subjugate the global market. Usually, for treatment and diagnosis of neurology-based disorders, patients take advice from a specialist and therefore, the hospital pharmacy is considered for prescription-based medication. This can be credited to the major share accounted by the segment in the market. 


The North American Region is Predicted to Dominate the Global Market

North America is projected to dominate and account for a prominent global epilepsy therapeutics market share. The North American region is prominently steered by a rising patient pool, a high number of incidences related to neurological disorders, injuries to the brain and increase in the number of epilepsy cases. Furthermore, developing products of high efficacy, better outcomes and having fewer side-effects shall possibly escalate the market growth in the region. The Asia Pacific region is predicted to inflate with a noteworthy growth rate over the forecast period. This is owing to the ever-increasing geriatric population base, initiatives taken by the government in order to improve the healthcare industry, increasing activities related to research and development and increasing prevalence of epilepsy in the Asia Pacific region. 


Key market players included in the global epilepsy therapeutics industry are Pfizer Inc., UCB S.A, Bausch Health Companies Inc., Novartis AG, GlaxoSmithKline PLC, Teva Pharmaceutical Industries, Sunovion Pharmaceuticals Inc., Eisai Co. Ltd., Upsher-Smith Laboratories LLC, Amneal Pharmaceuticals LLC.


Global Epilepsy Therapeutics Market Segmentation:

By Product

  • First Generation Epilepsy Therapeutics
  • Second Generation Epilepsy Therapeutics
  • Third Generation Epilepsy Therapeutics

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth


Objectives of the Study:

  • To provide with an exhaustive analysis on the global epilepsy therapeutics market by product, by distribution channel and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
  • To forecast and evaluate micro-markets and the overall market 
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
  • To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers


Get unlimited analyst support and customise this study further to your requirements, contact